Introduction In diffuse intrinsic pontine gliomas (DIPG), subtracting pre-contrast from post-contrast T1-weighted images (T1WI) occasionally reveals subtle, "occult" enhancement. We hypothesized that this represents intravascular enhancement related to angiogenesis and hence that these tumors should have greater blood volume fractions than do nonenhancing tumors. Methods We retrospectively screened MR images of 66 patients initially diagnosed with DIPG and analyzed pretreatment conventional and dynamic susceptibility contrast (DSC) perfusion MRI studies of 61 patients. To determine the incidence of occult enhancement, cerebral blood volume (CBV) values were compared in areas of occult enhancement (OcE), no enhancement (NE), and normal-appearing deep cerebellar white matter (DCWM). Results Tumors of 10 patients (16.4 %) had occult enhancement; those of 6 patients (9.8 %) had no enhancement at all. The average CBV in areas of occult enhancement was significantly higher than that in non-enhancing areas of the same tumor (P=.03), within DCWM in the same patient (P=.03), and when compared to anatomically paired/similar regions of interest (ROI) in patients with non-enhancing tumors (P=.005). Conclusion Areas of OcE correspond to areas of higher CBV in DIPG, which may be an MRI marker for angiogenesis, but larger scale studies may be needed to determine its potential relevance to grading by imaging, treatment stratification, biopsy guidance, and evaluation of response to targeted therapy.
Introduction
Approximately 11 % of central nervous system (CNS) tumors in children are brainstem tumors [1] , nearly 80 % of which are DIPGs, neoplasms associated with a dismal prognosis despite continued efforts to develop novel treatment strategies [2] . Available literature suggests that many of these neoplasms are actually high-grade (i.e., WHO grade 3 or 4) at diagnosis, and virtually all are glioblastoma multiforme at autopsy [3] [4] [5] . Because the conventional MRI features of DIPGs are considered to be virtually pathognomonic and the prognosis is nearly uniformly poor, the use of biopsy for histologic confirmation remains controversial [5] [6] [7] [8] . Therefore, identifying robust imaging biomarkers at the time of diagnosis that may indicate earlier or more advanced stages of the disease or different biological properties and correlating these features with outcome measures may have value for staging, therapeutic stratification, and prognostication.
One such imaging biomarker in tumors of the CNS (including DIPG) is signal enhancement on T1WIs after IV injection of gadolinium-based contrast agents. Inconsistent positive correlation between signal enhancement and histological tumor grade is well recognized in supratentorial gliomas [9] . In DIPGs specifically, a retrospective review evaluating the use of conventional MRI techniques to predict outcomes specifically found no prognostic significance of any conventional MRI features, including classic, overt enhancement (OvE) [10] , but another conflicting report of a larger study suggests an association between OvE and poor outcome measures [11] . Therefore, the correlation of OvE with DIPG outcome is currently still controversial.
We have occasionally observed a peculiar type of contrast enhancement in various cerebral neoplasms, including DIPGs, when pre-contrast T1WIs are subtracted from post-contrast T1WIs. This subtle web-like enhancement pattern that we refer to as "occult" (hidden) enhancement has not been reported in DIPGs or other brain tumors. We hypothesized that the histopathological substrate of occult enhancement (OcE) is early angiogenesis induced by tumor hypoxia rather than disruption of the blood-brain barrier (BBB), which is classically represented by OvE and typically associated with more advanced stages of the disease. If this is the case, tumors showing OcE should be characterized by a higher cerebral blood volume (CBV) than non-enhancing tumors.
Patients and methods

Patient accrual
This retrospective review of clinical and MRI data was approved by the institutional review board. A parent or legal guardian of each patient gave informed consent prior to enrollment into the applicable clinical therapeutic trials and protocol-based imaging studies.
Pretreatment baseline MR images of 66 patients initially diagnosed with DIPG (35 boys, 31 girls; median age at diagnosis 6.3 years, range 2.3-17.3 years) and enrolled in phase 1 and phase 2 treatment protocols at our institution from May 2007 through May 2011 were retrospectively reviewed for the presence of OcE on T1-weighted subtraction images. To limit the review to "classic" DIPGs, the five patients with atypical imaging or clinical features such as the following: (a) significant extrapontine extension, suggestive of gliomatosis cerebri (n=2), (b) tumor confined to the brainstem but not originating in the pons (n=1), or (c) overall survival (OS) greater than 3 years (n=2), were excluded from our review.
MR imaging
All but four MRI examinations were performed using a 3 T magnet (Siemens Trio, Siemens Medical Systems, Malvern, PA), and all were performed while the patient was under sedation or general anesthesia. The standard conventional imaging protocols included the following sequences: sagittal T1-weighted gradient-echo (TR:215 ms, TE:2.22 ms, flip angle:70), axial T1-weighted gradient-echo (TR:224 ms, TE:2.31 ms, flip angle:70), sagittal 3D T2-weighted (TR:3,000 ms, TE:3.46 ms), axial T2-weighted fast spinecho (TR:7,960 ms, TE:83 ms, flip angle:180), axial susceptibility-weighted (TR:27 ms, TE:20 ms, flip angle:15), axial echo-planar diffusion-weighted (TR:4,800 ms, TE:78 ms), gadolinium-enhanced sagittal 3D T1-weighted (TR:1,560 ms, TE:2.15 ms, flip angle:15), axial T1-weighted, coronal T1-weighted gradient-echo (TR:233 ms, T E : 2 . 2 2 m s , f l i p a n g l e : 7 0 ) , a n d a x i a l F L A I R (TR:10,000 ms, TE:103 ms, flip angle:130). A gadoliniumbased contrast agent (Magnevist, Bayer HealthCare Pharmaceuticals, Wayne, NJ) was used for contrast-enhanced imaging at an aggregate standard dose of 0.2 ml/kg (0.1 mmol/kg).
Dynamic susceptibility contrast (DSC) perfusion images were acquired as 15 contiguous sections (each 4 mm thick) of the entire brainstem and portions of the supratentorial brain and with a 256-square matrix to match the resolution of the conventional imaging. DSC perfusion images were acquired with an axial echo-planar gradient-echo sequence (TR: 1,800-1,980 ms, TE: 28 or 50 ms, flip angle: 90, 1 average). For preloading, 0.1 mL/kg IV gadolinium-based contrast agent was used. After 5 min, 50 image sets having a temporal sampling of 2 s were acquired during IV bolus reinjection of 0.1 mL/kg contrast followed by a 20-mL saline flush, both delivered by a power injector at the rate of 1-2 mL/s (depending on the maximum psi/flow rates recommended by the manufacturer of the IV line/port used in a given patient).
Analysis of perfusion data
OcE was defined as being a subtle, web-like signal enhancement that was unequivocally identified when pre-contrast T1WIs were subtracted from post-contrast T1WIs but that could not confidently be appreciated on post-contrast T1WIs without subtraction of the pre-contrast T1WIs. Since the tumor field in DIPGs may be quite heterogeneous and some patients in our series did have tumors which exhibited both OcE and OvE in different areas of the tumor, we included only patients with "pure" OcE (in the absence of OvE) in the OcE group. Patients with tumors exhibiting foci of both OvE and OcE were placed in the OvE group. Patients with no enhancement (NE) tumors had no evidence of either OcE or OvE.
DSC perfusion MRI data analysis was attempted for the 10 patients identified as having tumors with OcE on T1-subtraction images, but studies from 4 of those had to be excluded because of technical issues with data acquisition (n=2) or the presence of hemorrhage that generated inherent susceptibility artifacts in the OcE area (n=2). All six patients who had no enhancement, even on T1-weighted subtraction images, served as controls.
Because processing the perfusion imaging dataset to determine the brain's hemodynamic parameters relies heavily on the arterial input function, an iterative automated process using a Kohonen self-organizing map was used to identify the arterial input function from a constrained set of images at the level of the basilar artery. Then, perfusion imaging sets were analyzed by a truncated single-value deconvolution combined with a standard-form Tikhonov regularization with generalized cross-validation to yield parametric maps of CBV, flow, and mean transit times for all slices in the perfusion imaging set. Perfusion maps were then registered onto the T2 image with a nonlinear registration of local deformations by using a free-form deformation based on B-spline interpolation [12] .
Spatial normalization of the perfusion data was successful for 10 of 12 patients' images (four of six with OcE and all six with no enhancement). For the two patients with OcE but without satisfactory spatial normalization, regions of interest (ROIs) were placed directly on the perfusion image by using the corresponding T1-weighted subtraction image and T1WI for guidance. ROIs were then transferred from T1-subtraction images to perfusion maps, and CBV values were extracted.
A standard ROI (20×20 pixels) was drawn on axial T1-subtraction images of the four patients with OcE and successful spatial normalization by using ImageJ (National Institutes of Health) to sample OcE tumor, NE tumor, and DCWM, the latter represented normal parenchyma for referencing purposes. All ROIs were drawn by two reviewers, and final group assignments were decided by consensus. Identical ROIs were placed, preferably in anatomically corresponding tumor areas, in the NE control group to account for possible physiologic variations in brainstem vascularity. Representative ROIs are shown in Fig. 1 . Areas of necrosis or hemorrhage were avoided. Whenever possible, ROIs of patients with OcE were placed on the slice with the most obvious OcE area. However, ROIs were sometimes placed on an adjacent slice to avoid one or more sizeable (i.e., visible on subtraction images) intratumoral vessels which would "contaminate" the ROI. For unilateral OcE areas, the DCWM ROI was placed ipsilaterally to the OcE area. We also determined relative CBV (rCBV) values for both OcE and NE tumor areas, calculating CBV values relative to the internal standard, notably the normal-appearing DCWM. In our cases, this meant rCBV OcE = CBV OcE /CBVD DCWM and rCBV = CBV NE / CBVD DCWM .
Statistical evaluation
The Wilcoxon rank sum test was used to test the following: (1) whether the average CBV of patients with OcE was the same as that of those with NE; (2) whether the average CBVs extracted from OcE ROIs, NE ROIs, and DCWM ROIs were different within the OcE group; (3) whether the average rCBV was higher in areas of OcE than in NE areas of the same tumor; (4) whether the average rCBV within tumors of patients with no tumor enhancement was lower than that in areas of OcE in patients with OcE tumors; and (5) whether the average rCBV within tumors of patients with no tumor enhancement was different from that in NE areas of patients with OcE tumors. The Fisher's exact test was used to evaluate treatment randomization between the OcE and NE groups. All statistical analyses were performed by using SAS version 9.2 (SAS Institute, Cary, NC). Statistical significance was assumed when P<.05. Tables 1 and 2 , respectively. Within the OcE group, the average CBV and average rCBV in areas of OcE was significantly higher than in NE areas of the same tumor (CBV P=.0313, rCBV P=.0313). This was also true for average CBV in DCWM (P=.0313) ( Tables 3 and 4) .
Between the OcE and NE groups, both average CBV and average rCBV were significantly higher in OcE areas than in anatomically corresponding tumor areas in patients with no enhancement (CBV P=.0051; rCBV P=.0131) (Tables 5 and  6 ). The average CBVs in NE and DCWM ROIs were higher in the OcE group than in the NE group, but not significantly (NE ROIs, P=.13; DCWM ROIs, P=.18) ( Table 4) .
Discussion
To the best of our knowledge, subtraction positive, OcE in cerebral neoplasms has not been previously described in the literature. In this report, we provide a definition for this relatively rare MRI semiologic sign, report its incidence in DIPG, and using DSC perfusion analysis we propose an interpretation of the phenomenon in histopathological terms. Indeed, our data suggest that subtraction positive OcE in DIPG may be an MRI marker for angiogenesis.
A previous report of a smaller cohort of patients with DIPG found OvE in 51 % of baseline diagnostic MRI studies [10] . Our cohort had a higher percentage of tumors with OvE, and more than half of those without apparent enhancement had OcE, suggesting that some form of enhancement (overt or occult) is more common (90.2 %) than previously documented and that only a small percentage of DIPG patients may actually have completely NE tumors at the time of initial diagnosis.
As many other semiologic features in diagnostic imaging, OcE is not a binary category, but rather a spectrum (Fig. 2) , as is the level of expertise of radiologists involved in the care of patients with DIPG. Indeed, in some cases, more experienced investigators may be able to depict very subtle signal enhancement on post-contrast T1WIs even without subtraction, but the very same case may be considered equivocal or reported as NE by others. It is our experience that subtraction makes OcE unequivocal for all and is therefore a useful adjunct to the toolbox of the practicing radiologist.
The classic OvE pattern predominantly results from the extravasation of the IV-administered contrast agent through a disrupted BBB of eroded or newly formed, "imperfect", leaky microvasculature. OvE is often associated with higher histological grade in cerebral gliomas; however, it is also well known that the absence of OvE does not necessarily indicate low histological grade [13] [14] [15] [16] . Angiogenesis is necessary for tumor growth [14] , and the process of angiogenesis in response to tumor hypoxia in glioblastoma multiforme has been well described [13, [17] [18] [19] . The relationship between increased vascularity (i.e., angiogenesis) and elevated CBV in adult supratentorial gliomas is well-established too [20] [21] [22] [23] . Our finding of significantly higher CBVs in areas of OcE supports our hypothesis that OcE indicates early, regional expansion of the intravascular compartment and, thus, local angiogenic response to hypoxia, which at that stage is not yet associated with classically defined significant BBB insufficiency. Prominent intratumoral vessels (arteries or veins), which likely represent functional hypertrophy of normal vessels rather than angioneogenesis per se, may also be seen in DIPG, even without subtraction, hence may provide indirect evidence of increased blood flow in the tumor field (Fig. 2) . These vascular structures however are not suitable for the quantitative evaluation of the expansion of the vascular support system in DIPG, and whenever present, we actually tried to avoid those in our ROI-based measurements.
In our patients, all individual CBV values extracted from OcE areas were above the average CBV values of NE tumor areas and DCWM of both the OcE and NE groups, suggesting that OcE is associated with increased CBV and is a reliable and robust conventional MRI marker of angiogenesis, which may be evaluated on routine contrast-enhanced MRI studies in all clinical settings.
Data in the literature about the potential prognostic value of OvE in DIPG are controversial. Previous reports suggested that OvE was not a prognostic marker in DIPG [10, 24, 25] . Conversely, a study of 106 children with DIPG enrolled in clinical trials showed that OvE at baseline was associated with poorer progression-free survival and OS [11] .
The role of DSC perfusion MRI in the characterization of some other cerebral gliomas is better established. In adult supratentorial gliomas, increased rCBV is widely recognized as being a more robust predictor of outcome than is histopathological grade. Although several rCBV cut-off values to predict poor or more favorable outcome without histopathological grading have been published, the most widely accepted is that of 1.75, proposed by Law et al. [9] Increased rCBV values in DIPG were found to be associated with poorer outcome in one study [26] . This study, however, was based on nonquantitative CBV analysis.
Because in our cohort the average rCBV values in areas of OcE were above the 1.75 threshold, it is conceivable that DIPGs and other tumors with OcE may be associated with poorer outcomes than would those with no enhancement at all. However, whether rCBV threshold values established in adult supratentorial gliomas are appropriate for evaluating pediatric infratentorial gliomas, and if rCBV values in DIPG have similar prognostic value will require further study powered for analysis of key outcome measures, such as progressionfree survival and overall survival. The possibility of additional prognostic differences between OcE and OvE needs to be examined as well. We recognize that our study has limitations. First, although the relationship between CBV and increased vascularity is well-established in adult supratentorial gliomas, histologic verification was not possible in this study. Molecular biology data however suggest that some features in adult gliomas may not be directly applicable to DIPGs [27] . Second, because the purpose of this study was to investigate the perfusion properties of a particular form of contrast enhancement, we did not investigate the global perfusion properties of each tumor or, for example, explore the possibility of increased CBV in NE areas of tumors otherwise exhibiting OvE.
Despite these limitations, our study may have clinical implications. As our understanding of DIPG advances, genetic and molecular information obtainable only by biopsy may become increasingly pertinent for identifying different stages or subtypes of the disease that have potential relevance to prognostication and the likelihood of tumor response to specific targeted therapies [28] [29] [30] [31] re-introducing a role for histopathological confirmation and perhaps molecular biological characterization in the diagnosis of DIPG. In conventional MR images, most DIPGs show obvious inhomogeneities within the tumor field. The signal intensity variations likely correspond with histopathological changes such as hypercellularity [32] , hemorrhage [33] , necrosis, and edema. In fact, the potential usefulness and feasibility of using advanced MRI techniques for regional analysis of the tumor field has been shown for T2-hypointense foci characterized by decreased diffusion properties and increased CBV, which together seem to serve as surrogate imaging markers for foci of anaplasia and, therefore, for higher histopathological grade [32] . The ability to properly identify tumor regions harboring the highest-grade features for targeted biopsy may optimize grading [34] . Because hypoxia-induced angiogenesis likely occurs in areas of high tumor cell density and increased metabolic needs, we believe that OcE may represent a useful stereotactic biopsy site [32] , especially if associated with other MRI indicators of anaplasia. Furthermore, response to therapies targeting vascular endothelial growth factor receptors may also be optimally evaluated by monitoring rCBV and other perfusion metric changes in areas of OcE. 
Conclusions
Because the increased CBV in areas of OcE is likely a result of angiogenic expansion of the intravascular blood compartment within the tumor, our findings suggest that OcE may indeed be an MRI marker for hypoxia-induced angiogenesis in DIPG and, perhaps, in other cerebral neoplasms. OcE is an underappreciated form of contrast enhancement; hence, the incidence of contrast enhancement in DIPGs has likely been underestimated because OcE was not included in previous estimates. Clinically, OcE, in conjunction with other advanced MRI metrics (e.g., apparent diffusion coefficient values, choline/N-acetyl aspratate ratios) may be relevant for identifying a candidate stereotactic biopsy site for histopathological tumor characterization and provide opportunities to monitor the efficacy of antiangiogenic therapies.
